1. Home
  2. RIGL vs ALT Comparison

RIGL vs ALT Comparison

Compare RIGL & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • ALT
  • Stock Information
  • Founded
  • RIGL 1996
  • ALT 1997
  • Country
  • RIGL United States
  • ALT United States
  • Employees
  • RIGL N/A
  • ALT N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • RIGL Health Care
  • ALT Health Care
  • Exchange
  • RIGL Nasdaq
  • ALT Nasdaq
  • Market Cap
  • RIGL 335.5M
  • ALT 292.0M
  • IPO Year
  • RIGL 2000
  • ALT N/A
  • Fundamental
  • Price
  • RIGL $38.85
  • ALT $3.83
  • Analyst Decision
  • RIGL Buy
  • ALT Strong Buy
  • Analyst Count
  • RIGL 5
  • ALT 6
  • Target Price
  • RIGL $38.20
  • ALT $17.40
  • AVG Volume (30 Days)
  • RIGL 995.6K
  • ALT 3.0M
  • Earning Date
  • RIGL 08-05-2025
  • ALT 08-12-2025
  • Dividend Yield
  • RIGL N/A
  • ALT N/A
  • EPS Growth
  • RIGL N/A
  • ALT N/A
  • EPS
  • RIGL 5.43
  • ALT N/A
  • Revenue
  • RIGL $267,921,000.00
  • ALT $20,000.00
  • Revenue This Year
  • RIGL $59.93
  • ALT N/A
  • Revenue Next Year
  • RIGL N/A
  • ALT $761,880.20
  • P/E Ratio
  • RIGL $7.15
  • ALT N/A
  • Revenue Growth
  • RIGL 105.62
  • ALT N/A
  • 52 Week Low
  • RIGL $12.66
  • ALT $2.90
  • 52 Week High
  • RIGL $43.72
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 68.57
  • ALT 51.79
  • Support Level
  • RIGL $39.00
  • ALT $3.35
  • Resistance Level
  • RIGL $42.08
  • ALT $3.66
  • Average True Range (ATR)
  • RIGL 2.32
  • ALT 0.19
  • MACD
  • RIGL -0.37
  • ALT 0.07
  • Stochastic Oscillator
  • RIGL 53.26
  • ALT 86.18

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: